Is there a generic version of Revumenib available?

Revumenib is a new type of targeted drug mainly used to treat certain types of hematological malignancies. Due to its innovative mechanism of action and relatively new research and development background, Revimenib has not yet been launched in the domestic market, nor has it been included in the medical insurance system, which makes domestic patients temporarily unable to obtain the drug through formal channels. If patients need to use it, they usually have to rely on overseas channels for procurement.

From a price point of view, the price of the original drug version of Revimenib in overseas markets is relatively high. Taking the US market as an example, the packaging specifications of 110 mg 30 tablets and 160 mg 30 tablets may cost up to about 200,000 yuan per box. Prices are affected by exchange rate fluctuations and purchasing channels, and the actual amount paid may vary. This also reflects the high cost of Revimenib as an innovative drug, which puts certain pressure on patients’ financial burden of medication.

Regarding the situation of generic drugs, as of now, there is no generic version of Revimenib available for sale in any country or region. Due to its short research and development time and patent protection period, there are no similar generic products on the market, and patients can only choose the original drug. In the future, as patent protection expires or technology advances, generic drugs may gradually appear. By then, drug prices and drug accessibility are expected to improve.
To sum up, Revimani, as a high-end innovative targeted drug, is currently not available in the domestic market and is not supported by medical insurance. The overseas price is high and there are no generic drugs available. If patients need to use this drug, they should weigh the efficacy and economic factors under the guidance of a professional doctor, and choose to purchase it through regular channels to ensure the safety and effectiveness of the drug.
Reference: https://www.drugs.com/